May 2, 2022
RegMed Investors’ (RMi) closing bell: the oversold were noticed but, for how long?
April 29, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector dives, TGIF and April is over
April 28, 2022
RegMed Investors’ (RMi) closing bell: gravity was overcome for the cell and gene therapy sector
April 27, 2022
RegMed Investors’ (RMi) closing bell: wherefore art thou sentiment
April 25, 2022
RegMed Investors’ (RMi) closing bell: big share price reversal helps resets the cell and gene therapy sector’s oversold
April 22, 2022
RegMed Investors’ (RMi) closing bell: what happened today, another sector face plant in the mud
April 21, 2022
RegMed Investors’ (RMi) closing bell: market conditions and sector sentiment are hammered
April 20, 2022
RegMed Investors’ (RMi) closing bell: low volume lethargy enables fatigued sentiment hampering some share pricings
April 19, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector’s ascension
April 18, 2022
RegMed Investors’ (RMi) closing bell: Why the slide …
April 14, 2022
RegMed Investors’ (RMi) closing bell: closing with a downslide shortened week with Friday market holiday
April 12, 2022
RegMed Investors’ (RMi) closing bell: snap, crackle and no pop as liquidity drains from the sector as indexes dives again
April 8, 2022
RegMed Investors’ (RMi) closing bell: it will pay to be early in buying newest bottoms
April 6, 2022
RegMed Investors’ (RMi) closing bell: uncertainty trips upside momentum
April 5, 2022
RegMed Investors’ (RMi) closing bell: rough ride with news spelling share pricing risk
April 4, 2022
RegMed Investors’ (RMi) closing bell: back on top in a tricky environment for cell and gene therapy sector equities
April 1, 2022
RegMed Investors’ (RMi) closing bell: an uptick for the oversold
March 31, 2022
RegMed Investors’ (RMi) closing bell: struggling for direction with fading optimism as March and Q1 end
March 30, 2022
RegMed Investors’ (RMi) closing bell: the impact of doubts about the strength of a recent market rebound
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.